Key result
RYR1 variants linked to recurrent rhabdomyolysis in neuroleptic malignant and serotonin syndromes.
Why the study?
The molecular bases of neuroleptic malignant syndrome and serotonin syndrome remain poorly understood, despite phenotypic overlap with syndromes carrying clear genetic backgrounds like RYR1-related malignant hyperthermia.
Population
134 patients from 10 case series and 99 case reports
Design
Literature review according to PRISMA guidelines
Authors
Loading...
Recurrent rhabdomyolysis may signal genetic susceptibility; hypothesis-generating for RYR1 variants, prospective validation required.
Systematic Review (n=134)
A subset of patients with neuroleptic malignant syndrome and serotonin syndrome develop recurrent rhabdomyolysis, suggesting a possible underlying genetic susceptibility that warrants further investigation.
Kruijt et al. (2020) conducted a systematic review in Neuroleptic malignant syndrome and serotonin syndrome (n=134). Genetic testing was evaluated on Clinical features and results of genetic testing. In a review of 134 patients with neuroleptic malignant or serotonin syndrome, genetic testing in 11 patients (8%) revealed four RYR1 variants, and 8 patients experienced recurrent rhabdomyolysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: